1
Damian O Arnaiz, Yuo Ling Chou, Brian D Griedel, Rushad E Karanjawala, Monica J Kochanny, Wheeseong Lee, Amy Mei Liang, Michael M Morrissey, Gary B Phillips, Karna Lyn Sacchi, Steven T Sakata, Kenneth J Shaw, R Michael Snider, Shung C Wu, Bin Ye, Zuchun Zhao: Ortho-anthranilamide derivatives as anti-coagulants. Berlex Laboratories, Carol J Roth, October 31, 2000: US06140351 (61 worldwide citation)

This invention is directed to compounds of formula (III): ##STR1## wherein B, C, D, E, R.sup.1, R.sup.2 and R.sup.3 are disclosed herein. These compounds are disclosed as being useful as anti-coagulants.


2

3
Shripad S Bhagwat, Yoshitaka Satoh, Steven T Sakata, Chris A Buhr, Ronald Albers, John Sapienza, Veronique Plantevin, Qi Chao, Kiran Sahasrabudhe, Rachel Ferri: Indazole derivatives as JNK inhibitors and compositions and methods related thereto. Signal Pharmaceuticals, Jones Day, May 24, 2005: US06897231 (24 worldwide citation)

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive ...


4
Shripad S Bhagwat, Yoshitaka Satoh, Steven T Sakata, Chris A Buhr, Ronald Albers, John Sapienza, Veronique Plantevin, Qi Chao, Kiran Sahasrabudhe, Rachel Ferri: Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith. Signal Pharmaceuticals, Jones Day, May 1, 2007: US07211594 (14 worldwide citation)

This invention is generally directed to Indazole Derivatives having the following structure: or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhi ...


5
Shripad S Bhagwat, Yoshitaka Satoh, Steven T Sakata, Chris A Buhr, Ronald Albers, John Sapienza, Veronique Plantevin, Qi Chao, Kiran Sahasrabudhe, Rachel Ferri: Methods of using indazole derivatives as JNK inhibitors. Signal Pharmaceuticals, Jones Day, May 22, 2007: US07220771 (12 worldwide citation)

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive ...


6
Shripad S Bhagwat, Yoshitaka Satoh, Steven T Sakata, Chris A Buhr, Ronald Albers, John Sapienza, Veronique Plantevin, Qi Chao, Kiran Sahasrabudhe, Rachel Ferri: Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith. Signal Pharmaceuticals, Jones Day, April 24, 2007: US07208513 (11 worldwide citation)

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive ...


7

8
Steven T Sakata, Heather K Raymon: Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related. Signal Pharmaceuticals, Jones Day, January 17, 2006: US06987184 (10 worldwide citation)

Isothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof having the general formula: and pharmaceutically acceptable salts thereof, wherein R0 is —CH2—, —SO—, —O—, —SO2—, or —S—; compositions comprising the isothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, an ...


9
Steven T Sakata, Heather K Raymon: Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto. Signal Pharmaceuticals, Jones Day, April 8, 2008: US07354947 (8 worldwide citation)

Isaothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof having the general formula: and pharmaceutically acceptable salts thereof, wherein R0 is —CH2—, —SO—, —O—, —SO2—, or —S—; compositions comprising the iazoloanthrones, isooxazoloanthrones, isoindolanthrones, and de ...


10